While tumor cells can adapt and survive when either single pathway is inhibited, combined inhibition of PI3K/AKT and AR signaling using the PI3K/mTOR inhibitor BEZ235 and the AR antagonist enzalutamide (ENZ) significantly delayed castrate‐resistant LNCaP tumor progression. Here, AR is linked to neoplasm.